Supriya Lifescience Limited — Investor Meet, 02-06-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Supriya Lifescience reported strong Q4 FY26 with INR 277 Cr revenue (+50% YoY) and INR 98 Cr EBITDA (+44% YoY, 35.5% margin). FY26 revenue hit INR 828 Cr (+19% YoY), meeting target, with EBITDA at INR 294 Cr (35.5% margin). Noted USFDA EIR for Lote facility after a surprise inspection. Launched new cardiovascular, ADHD, and anesthetic products; contrast media in H2 FY27. Guided for INR 1,000 Cr revenue by FY27 (~20% annual growth, 33-35% EBITDA margin). Capacity expansion at Patalganga and Lote F block are key priorities. Management expresses confidence in achieving growth targets.